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Abstract
In vivo studies of the metastatic process are severely hampered by the fact that most human tumor cell lines derived from
highly metastatic tumors fail to consistently metastasize in immunodeficient mice like nude mice. We describe a model
system based on a highly immunodeficient double knockout mouse, Rag2
2/2;Il2rg
2/2, which lacks T, B and NK cell activity.
In this model human metastatic HER-2
+ breast cancer cells displayed their full multiorgan metastatic potential, without the
need for selections or additional manipulations of the system. Human HER-2
+ breast cancer cell lines MDA-MB-453 and BT-
474 injected into Rag2
2/2;Il2rg
2/2 mice faithfully reproduced human cancer dissemination, with multiple metastatic sites
that included lungs, bones, brain, liver, ovaries, and others. Multiorgan metastatic spread was obtained both from local
tumors, growing orthotopically or subcutaneously, and from cells injected intravenously. The problem of brain recurrencies
is acutely felt in HER-2
+ breast cancer, because monoclonal antibodies against HER-2 penetrate poorly the blood-brain
barrier. We studied whether a novel oral small molecule inhibitor of downstream PI3K, selected for its penetration of the
blood-brain barrier, could affect multiorgan metastatic spread in Rag2
2/2; Il2rg
2/2 mice. NVP-BKM120 effectively controlled
metastatic growth in multiple organs, and resulted in a significant proportion of mice free from brain and bone metastases.
Human HER-2
+ human breast cancer cells in Rag2
2/2;Il2rg
2/2 mice faithfully reproduced the multiorgan metastatic pattern
observed in patients, thus allowing the investigation of metastatic mechanisms and the preclinical study of novel
antimetastatic agents.
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Introduction
Metastatic dissemination is the most feared sequel of cancer,
and the main cause of mortality. Dissemination from primary
tumors can reach every organ in the body, however each tumor
type displays a specific metastatic pattern resulting from the
interaction of tumor-intrinsic and organ-specific molecular and
cellular properties [1,2]. For example, the most common targets of
breast cancer dissemination are the bones, the lungs, abdominal
viscera and the brain [3–6]. Metastatic patterns determine the
duration of recurrence-free intervals and, more importantly,
quality of life and overall survival.
The study of metastatic dynamics in cancer patients is
constrained by practical and ethical issues, therefore the availabil-
ity of representative animal models is critical. Unfortunately, the
metastatic potential of human tumors and cell lines is expressed
incompletely in current animal models [7,8].
Modifications of experimental conditions brought significant
improvements, for example using special injections routes (e.g.
intracardiac or intracarotid), or cell variants selected for enhanced
organ-specific metastasis [9–12]. However, such expedients
resulted in preclinical models that are further removed from
relevant clinical aspects of metastatic dissemination. This problem
is acutely felt in the field of metastatic breast cancer, because most
studies are based on a handful of metastatic cell lines (in particular
MDA-MB-231 and MDA-MB-435), whereas relevant pathological
groups, such as HER-2
+ tumors, lack representative metastatic
models. The only solution so far has been to force HER-2
expression in existing HER-2-negative cell lines through gene
transduction [13]. However it is unclear whether this approach
faithfully models both HER-2 hyperexpression resulting from
spontaneous carcinogenesis and the ensuing response of metastatic
breast cancer to targeted agents.
An alternative to the manipulation of tumor cells would be the
use of more permissive hosts. The major problem with classical
nude mice is their intact NK activity, that severely impairs
metastatic dissemination [14]. Pioneering studies using different
immunodeficient mutants, like scid or NIH-III mice, did not reveal
sizeable advantages [15,16]. An initial solution was the pretreat-
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opened only a narrow temporal window, unsuitable for studies of
metastatic dissemination from local tumors, furthermore complete
NK depletion could not be reached, especially at the tissue level.
The advent of genetically-modified mice, with specific and
stable immune defects, provided novel hosts for the study of
human metastatic tumors [3,8,17]. We have recently shown
that Rag2
2/2;Il2rg
2/2 (also called Rag2
2/2;gammac
2/2)
mice, which lack T, B and NK cells [18], allow the metastatic
spread of human musculo-skeletal sarcomas, and are vastly
superior to NK-depleted nude mice [7]. We show here that, in
Rag2
2/2;Il2rg
2/2 mice, the metastatic pattern of human HER-2
+
breast cancer reproduces the multiorgan dissemination seen in
patients, allowing meaningful studies of antimetastatic approaches.
Results
Tumor growth and metastatic spread in Rag2
2/2;Il2rg
2/2
mice
Many human breast cancer cell lines, in particular those
expressing HER-2, grow poorly in nude mice [19,20], and usually
do not metastasize, even when NK activity is temporarily blocked
by treatment of the host with NK-depleting antibodies. Table 1
shows that, after subcutaneous injection, HER-2
+ MDA-MB-453
and BT-474 cells did not give rise to tumors in nude mice
(with a minimum follow-up of 15 weeks). The same cells in
Rag2
2/2;Il2rg
2/2 mice gave rise to progressive local tumors after
very short latency times (Table 1), both after subcutaneous and
orthotopic (intramammary) administration.
Metastatic dissemination of MDA-MB-453 and BT-474 cells in
Rag2
2/2;Il2rg
2/2 mice was widespread, and reached all sites
commonly affected in human patients, including lungs, liver, bones
and brain (Table 2). Multiorgan metastatic dissemination did not
show age-related differences within the age range studied.
Interestingly, all administration routes led to the development of
multiorgan metastases.
Different metastatic burdens were observed in different organs,
and the use of EGFP-tagged cells was instrumental in allowing a
precise detection of metastatic nodules throughout the body.
Figure 1 shows representative pictures of multiorgan metastatic
dissemination of 453-EGFP (panels A-H) and 474-EGFP (panels
I-K) cells in Rag2
2/2;Il2rg
2/2 mice. Figures 1A and 1B show two
mice with multiple bones metastases, a metastatic localization that
became apparent with the use of fluorescence detection.
Figures 1C-H show dissected organs with representative pictures
of metastatic dissemination to lungs, brain, ovaries, liver, kidneys
and adrenals. Figure 1I shows the dissemination of a primary 474-
EGFP tumor, growing in an abdominal mammary gland, to an
axillary lymph node. Figures 1J-K show a dissected femur and
liver with 474-EGFP metastases.
Brain metastases
The brain is a common site of metastatic spread, but tumor
growth in immunodeficient mice fails to reproduce this fateful
property of human tumors, unless unique cell lines, selected variants
and/or special injection routes are used. In contrast, brain
metastases were common in Rag2
2/2;Il2rg
2/2 implanted with
HER-2+mammarycarcinomacells,makingtheRag2
2/2;Il2rg
2/2
mouse an exquisite model for the study of brain dissemination.
Morphologic analysis of brain deposits stained with anti-HER-2
antibody (Figure 2) showed that mice implanted with MDA-MB-
453 (Fig. 2A-B) or BT-474 (Figure 2C) cells had multiple
metastases with a distribution recapitulating the clinical situation
observed in breast cancer patients developing brain metastasis.
Intracerebral and intraventricular or leptomeningeal metastases
were detected, ranging from minimal deposits of few cells to
prominent masses. Most intracerebral metastases were located in
the cerebrum with rare nodules in the cerebellum. As in patients,
intracerebral metastases commonly grew at the junction between
white and grey matter (cortex and basal ganglia). Leptomeningeal
metastases occurred with invasion and proliferation of neoplastic
cells in the subarachnoid space. Multifocal infiltration of the
leptomeninges in a sheetlike fashion along the surface of the brain
and, sometimes, dissemination in the intraventricular spaces were
also observed.
Therapy of disseminated human breast cancer
Metastatic dissemination of human breast cancer is a great
therapeutic challenge. Current therapies have led to an improved
control of the systemic disease and consequently modified the risk
of metastatic relapse in different organs. For example, the
monoclonal antibody trastuzumab appears to enhance the risk of
Table 1. Tumor growth of human breast cancer cell lines in Rag2
2/2;Il2rg
2/2, but not in nude mice.
Mice Cell line Route Tumor incidence
Latency time
(wk ± SEM)
Tumor volume
a
(cm
3 ± SEM)
Nude MDA-MB-453 subcutis 0/3
b ––
Rag2
2/2;Il2rg
2/2 MDA-MB-453 subcutis 21/21 1.460.24 0.9060.16
MDA-MB-453 intramammary 8/8 1.860.06 0.5260.16
Rag2
2/2;Il2rg
2/2 453-EGFP subcutis 3/3 1.060.00 0.8460.29
453-EGFP intramammary 7/7 1.360.18 0.4060.18
Nude BT-474 subcutis 0/3
b ––
Rag2
2/2;Il2rg
2/2 BT-474 subcutis 10/10 1.760.70 2.6460.35
BT-474 intramammary 5/5 2.661.60 1.7260.77
Rag2
2/2;Il2rg
2/2 474-EGFP subcutis 6/6 2.760.49 2.2660.68
474-EGFP intramammary 6/6 1.060.00 1.6160.59
Abbreviations: wk, weeks; SEM, standard error of the mean.
aTumor volumes at 12–13 weeks after cell injection, except 474-EGFP at 23 weeks.
bAll nude mice were tumor-free 15 weeks after cell injection.
doi:10.1371/journal.pone.0039626.t001
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penetration of the blood-brain barrier [21]. New treatments are
urgently needed to address this new patient population. A mouse
model of multiorgan metastatic dissemination is an important tool
to investigate new antimetastatic drugs.
We studied whether NVP-BKM120 [22,23], a selective PI3K
inhibitor with a demonstrated penetration of the blood-brain
barrier, could control the metastatic growth of 453-EGFP cells in
different target organs. Oral NVP-BKM120 produced a strong
and widespread reduction in the metastatic burden (Figure 3). The
therapeutic activity of NVP-BKM120 was more evident on
metastatic localizations (Figure 3A) than on local tumor growth
(Figure 3B). In multiple sites a sizeable proportion of mice were
noted to be metastasis-free following 7–12 weeks of treatment
(Figure 3A and 3C). Even in the more heavily colonized organs,
such as the brain, NVP-BKM120 strongly inhibited the growth of
453-EGFP (Figure 3D).
To better assess NVP-BKM120 therapeutic activity against
metastases, we quantitated metastatic cells using human-specific
Real-Time PCR or HER-2 flow cytometry. In the brain of mice
treated with NVP-BKM120 we found a .90% inhibition in the
number of human cells with both technologies (Figure 4A and B),
thus confirming the potential of this drug against brain metastases.
HER-2+ cells were reduced by 71% in the bone marrow
(Figure 4C), and the number of metastatic bone localizations
was decreased by 67% (Figure 4D). Metastases to kidneys and
adrenal glands were also greatly reduced (Figure 4E). Globally,
NVP-BKM120 reduced by more than 50% the number of
metastatic sites per mouse (Figure 4F).
Discussion
We described a model system in which metastatic human cells
displayed their full multiorgan metastatic potential, without the
need for selections or additional manipulations. In particular, a
critical issue in the study of human breast cancer spread, i.e. brain
metastases, was faithfully reproduced in our system. It is
noteworthy that human HER-2
+ breast cancer cells produced
metastases in many organs both after local tumor growth (either
orthotopic or subcutaneous) and after intravenous administration.
The results of this work have both practical and theoretical
relevance. From a practical point of view, the demonstration that
Rag2
2/2;Il2rg
2/2 mice are permissive for the metastatic spread
of human HER-2
+ breast cancer solves the long-standing problem
of investigating multiorgan metastatic mechanisms of human
cancer in preclinical mouse models. Various attempts made in the
past to enhance metastatic spread through the use of immunode-
ficient rodents different from nude mice [15,24], or of immuno-
suppressive treatments administered to nude mice [7] had limited
success. It is commonplace to study only the few human cell lines
that, for unknown reasons, metastasize in nude mice, and to use
such cell lines as a platform for the transduction of unexpressed
genes, e.g. HER-2, and for the selection of more metastatic, or
organ-specific cell variants [11,25]. In summary, previous mouse
models of metastatic spread of human tumors were affected by
Table 2. Multiorgan metastatic ability of human breast cancer cell lines in Rag2
2/2;Il2rg
2/2 mice.
Cell line
Metastasis
origin
Mice with
metastases
a
Mice with
multiorgan
metastases Metastatic sites
Brain Lung Liver Ovary
Kidney,
adrenal Bone
Bone
marrow
Lymph
node Other
b
MDA-MB-453 Orthotopic tumor 4/4 (100%) 4/4 (100%) 33 3 3 3 3
453-EGFP Orthotopic tumor 11/11 (100%) 10/11 (91%) 3333 3 3 3 3 3
BT-474 Orthotopic tumor 2/3 (67%) 1/3 (33%) 33 3 3
474-EGFP Orthotopic tumor 6/6 (100%) 4/6 (67%) 3333 3 3 3 3
MDA-MB-453 Subcutaneous
tumor
14/14 (100%) 14/14 (100%) 33 3 3 3 3
453-EGFP Subcutaneous
tumor
3/3 (100%) 3/3 (100%) 3333 3 3 3 3
BT-474 Subcutaneous
tumor
1/8 (13%) 1/8 (13%) 33 3
474-EGFP Subcutaneous
tumor
5/5 (100%) 4/5 (80%) 33 3 3 3
MDA-MB-453 Intravenous
injection
c
16/16 (100%) 16/16 (100%) 3333 3 3 3
453-EGFP Intravenous
injection
c
12/12 (100%) 12/12 (100%) 3333 3 3 3 3 3
BT-474 Intravenous
injection
c
13/13 (100%) 10/13 (77%) 3333 3 3 3
474-EGFP Intravenous
injection
c
3/6 (50%) 1/6 (17%) 33 3
aTable includes only those mice for which all indicated metastatic sites were homogeneously evaluable, excluding, for example, those cases in which selected organs
were separately processed for morphologic or immunohistochemical studies (see Fig. 2).
bOther metastatic sites include salivary glands, snout, uterus, interscapular space.
cMice were sacrificed when they showed signs of distress; mean 6 standard error of the mean survival times in weeks were: MDA-MB-453: 9.160.32; 453-EGFP:
8.460.57; BT-474: 28.963.36; 474-EGFP: 59.364.92.
doi:10.1371/journal.pone.0039626.t002
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fundamental and in translational studies. Furthermore, in most
instances, such models were restricted to a single metastatic
localization [26].
We have shown here that Rag2
2/2;Il2rg
2/2 mice allow the
metastatic spread of human HER-2+ breast cancer cells, recapitu-
lating the clinical situation. We have previously shown that the
same is true for an entirely different group of human tumors,
Figure 1. Representative images of metastatic dissemination of human breast cancer cells in Rag2
2/2;Il2rg
2/2 mice. In each picture
metastases are bright green, clearly distinct from either brownish internal organs or yellow autofluorescence of mouse skin and fur. Panels A-H, 453-
EGFP cells; panels I-K, 474-EGFP cells. Routes of injection: intravenous (A, B, G); subcutaneous (D, E, H); intramammary (C, F, I, J, K). (A) Ventral view of a
mouse showing multiple metastases prevalently affecting bones. Bar corresponds to 10 mm. (B) Dorsal view of a mouse showing bone and brain
metastases. Bar corresponds to 10 mm. (C) Dissected lungs showing widespread metastatic dissemination. Bar corresponds to 3.3 mm. Dorsal (D) and
ventral (E) views of a dissected brain with multiple metastases. Bar corresponds to 3.3 mm. (F) Dissected ovaries and uterus with one large ovarian
metastasis. Bar corresponds to 5 mm. (G) Dissected liver with metastases. Bar corresponds to 10 mm. (H) Dissected kidneys and adrenal glands with
multiple bilateral metastases. Bar corresponds to 10 mm. (I) Dissected primary tumor disseminating from the abdominal mammary gland to an
axillary lymph node. Bar corresponds to 5 mm. (J) Dissected femur with metastasis. Bar corresponds to 5 mm. (K) Dissected liver with metastases. Bar
corresponds to 9.2 mm.
doi:10.1371/journal.pone.0039626.g001
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Rag2
2/2;Il2rg
2/2 mice could unveil the intrinsic tumorigenic and
metastatic potential of human cancer cells, which is masked or
distorted bythe use of poorlypermissive hosts. Our results prompt for
comprehensive and comparative studies of further tumor histotypes,
using both cell lines and primary tumor samples.
An important application of this new in vivo model would be the
prediction of the metastatic propensity and organ tropism of
individual tumors, since current prognostic parameters provide
only a probabilistic evaluation. For example, some node-negative
breast cancer patients develop metastases, whereas some node-
positive patients do not. Furthermore, while the general pattern of
metastatic spread is known [1,4], the specific organ tropism of
individual cancers is unpredictable. Such knowledge would be of
paramount importance to further the concept of individualized
therapies, through organ-focused antimetastatic therapies tailored
to individual risk of recurrence. Future studies should investigate
whether Rag2
2/2;Il2rg
2/2 mice, in combination with molecular
signatures and cellular assays, could be used to predict metastatic
ability of individual tumors [27].
Relevant conceptual implications of our results concern both
metastasis biology and tumor immunity. In the past it was
hypothesized that the low metastatic ability of human tumor cells
in immunodeficient (nude) mice was caused by inappropriate
receptor-counterreceptor interactions involving xenogeneic (i.e.
human and murine) molecules. If this were the case, to obtain a
good metastasis-prone mouse, a myriad of mouse genes would
have to be replaced with human equivalents. On the contrary,
Rag2
2/2;Il2rg
2/2 mice demonstrate that the immune system is
the major obstacle to efficient human metastasization in mice, and
that a combined immunodeficiency is sufficient to permit the
systemic spread of human tumor cells.
When compared to Rag2
2/2;Il2rg
2/2 mice, nude mice display
an impressive resistance to human tumor cell growth and
malignancy (Tab. 1 and [7]), thus suggesting that the differential
immunological mechanisms could be exploited for antimetastatic
therapies. It is noteworthy that major functional differences
between nude and Rag2
2/2;Il2rg
2/2 mice, i.e. B and NK cells,
are underexploited in current immunotherapies [28]. The
relevance of B cells and antibodies in cancer immunoprevention
and immunotherapy is demonstrated not only by the clinical
impact of monoclonal antibodies, but also by a large body of
studies focused on HER-2 in mammary carcinoma [29], leading to
the development of clinical vaccines that stimulate both T and B
cell immunity [30].
The importance of NK cells in the control of metastatic
spread has long been recognized [14], however therapeutic
applications so far remain at the experimental stage of develop-
ment. One possible hint for novel developments comes from the
fact that systemic treatments against NK cells administered to
nude mice had a limited effect on human tumor cell spread, unlike
Rag2
2/2;Il2rg
2/2 mice which have a generalized NK deficiency.
This points to an important role of organ-specific NK cells, a set of
NK populations so far not exploited by cancer immunotherapies.
A further advantage of Rag2
2/2;Il2rg
2/2 mice is that they can
be engrafted with hemopoietic stem cells, thus giving rise to a
functioning human immune system [18]. The combination of
immune reconstitution and metastatic permissiveness allows for
the first time the analysis of natural and adaptive immune
responses against human tumors and metastases growing in vivo,
and the investigation of immunotherapeutic maneuvers aimed at
eliciting selected immune activities [De Giovanni et al., manu-
script in preparation].
The development of novel antimetastatic drugs is another field
to which realistic preclinical models could contribute significant
advances [31]. Most drugs currently in clinical use, including small
molecules and monoclonal antibodies, underwent in vivo preclinical
development mainly in nude mice bearing local tumors. Evalu-
ation of organ-specific antimetastatic activity is increasingly
important today, as monoclonal antibodies and other targeted
therapeutic agents have modified the pattern of metastatic
recurrence, and increased the incidence of specific localizations,
such as the brain [21,32,33].
MDA-MB-453 breast cancer cells used in this work were
resistant to the antiproliferative activity of trastuzumab in vitro (our
unpublished results and [34]), therefore the results shown here
Figure 2. Morphologic aspects of HER-2-positive brain metas-
tases in Rag2
2/2;Il2rg
2/2 mice. Immunohistochemical staining for
HER-2. (A) Intracerebral metastases after s.c. tumor growth of MDA-MB-
453 (magnification x50, bar corresponds to 200 mm). (B) Intraventricular
metastasis after s.c. tumor growth of MDA-MB-453 (magnification6400,
bar corresponds to 20 mm). (C) Large cerebral metastasis after i.v.
injection of BT-474 cells. (magnification 650, bar corresponds to
200 mm).
doi:10.1371/journal.pone.0039626.g002
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+ breast
cancer progressed in the brain and other organs after anti-HER-2
monoclonal antibody therapy. The efficacy of NVP-BKM120 in
controlling metastatic growth in multiple organs, including the
brain, forecasts clinical impact in analogous clinical situations of
this novel oral pan-PI3K inhibitor.
Materials and Methods
Ethics Statement
All experiments were performed according to Italian and
European guidelines and were specifically authorized by the
Animal Care and Use Committee of the University of Bologna
(project sent to the Italian Ministry of Health with letter n. 12511-
X/10, supervisor: Prof. Carla De Giovanni).
Mice
Rag2
2/2;Il2rg
2/2 (elsewhere referred to as Rag2
2/2;gam-
ma
c2/2) breeders were kindly given by Drs. T. Nomura and M.
Ito of the Central Institute for Experimental Animals (Kawasaki,
Japan). Nine–20-week-old female Rag2
2/2;Il2rg
2/2 mice, bred
in our animal facilities under sterile conditions, were used
throughout this work. Six-8-week-old female athymic Crl: CD-1-
Foxn1
nu/nu mice (referred to as nude mice) were purchased from
Charles River Italy and kept under sterile conditions.
Cell lines
MDA-MB-453 [35] and BT-474 [36] breast cancer cell lines
were originally obtained from Dr. Serenella M. Pupa (Istituto
Nazionale dei Tumori, Milan, Italy). Cell lines were authenticated
by DNA fingerprinting on the 11
th November 2010 (performed by
DSMZ, Braunschweig, Germany). Cells were routinely cultured in
Roswell Park Memorial Institute (RPMI) medium supplemented
with 10% foetal bovine serum and were maintained at 37uCi na
humidified 5% CO2 atmosphere. All medium constituents were
purchased from Invitrogen, Milan, Italy. To visualize metastatic
deposits, breast cancer cell lines were transfected with a plasmid
expressing Enhanced Green Fluorescent Protein (pEGFP-N1,
Clontech, Mountain View, CA) using Lipofectamine 2000
(Invitrogen). Stable transfectants were selected using G418
(Invitrogen). EGFP expression was monitored by fluorescence
microscopy and quantified by cytofluorometric analysis.
Metastasis induction
Local tumors were induced with 10
7 viable human cells injected
either subcutaneously in the right hind leg in 0.2 ml of PBS, or in
the fat pad of the fourth (abdominal) left mammary gland in 0.1 ml
of PBS. Intramammary administration was performed by reaching
with a 29-gauge syringe needle the area underlaying the nipple
and the areola, and observing the formation of a swelling under
that area (modified from [37]). Tumor diameters were periodically
measured with digital calipers; tumor volumes were calculated as
p/2?[!(a?b)]
3/6, where a=maximal tumor diameter and b=major
tumor diameter perpendicular to a. For intravenous (i.v.)
administrations, 2 million cells in 0.4 ml PBS were injected in a
tail vein. Pilot experiments were performed to assess for each
cell line the time at which experimental metastases could be
detected.
Metastasis detection and quantification
Tumor-bearing mice were sacrificed at various times (see
Results), depending on tumor and metastasis growth, and were
subjected to an accurate necropsy. Lungs were perfused with black
India ink to better outline metastases and fixed in Fekete’s
solution. Lung and liver metastases were counted using a
dissection microscope. When EGFP-expressing cells were injected,
whole mice and dissected organs were carefully examined using a
Lightools imaging system (Lightools Research, Encinitas, CA) to
detect fluorescent metastatic deposits. Quantification of metastatic
load in brain and bone marrow was performed by immunofluo-
rescence followed by cytofluorometric analysis and by Real-Time
PCR. Brain was minced with scissors and passed through a 70 mm
cell strainer (Becton Dickinson, Bedford, MA, USA) to obtain a
homogeneous cell suspension. Bone marrow was flushed from
both femurs in PBS and filtered through a 70 mm strainer. A
mouse monoclonal antibody against human HER-2 (clone Neu
24.7, Becton Dickinson, San Jose, CA, USA) labeled with
phycoerythrin was used to quantify human cells by cytofluoro-
metric analysis. Real-Time PCR was performed on genomic DNA
extracted with 10 mM Tris-HCl buffer pH 8.3 containing 50 mM
KCl, 2.5 mM MgCl2, 0.01% gelatin, 0.45% igepal, 0.45% tween
20 and 120 mg/ml proteinase K (all reagents from Sigma, Milan,
Italy) by an overnight incubation at 56uC followed by 30 min
incubation at 95uC to inactivate the proteinase K. A sequence of
the a-satellite region of the human chromosome 17 was amplified.
Primer and probe sequences were derived from Becker et al. [38],
with the sole alteration that the probe carried the non-fluorescent
quencher dye TAMRA at the 39-end. A 100 ng DNA aliquot per
sample was amplified using 250 nM primers and 100 nM probe in
a final volume of 25 ml of TaqMan Universal PCR Master Mix
(Applied Biosystems, Milan, Italy). After an initial denaturation
step at 95uC for 10 min, 45 cycles of amplification (95uC for
30 sec plus 60uC for 1 min) were performed in a 5700 Sequence
Detection System (Applied Biosystems). DNA extracted from
mouse tissues showed no amplification up to 45 cycles. To
quantify human cells, a standard curve was constructed by adding
scalar amounts of MDA-MB-453 human cells to cells from the
mouse whole brain. Ct (threshold cycle) values obtained from the
experimental samples were interpolated in the standard curve run
in each PCR.
Anti-metastasis therapy with NVP-BKM120
NVP-BKM120 (Novartis Institutes for BioMedical Research –
Oncology, Basel, Switzerland) was formulated in 1-methyl–2-
pyrrolidone (NMP)/poly–ethylene glycol 300 (Fluka) (10/90, v/v).
Solutions (7.5 mg/ml) were prepared fresh each day of treatment
and carefully shielded from light. Groups of 5–9 Rag2
2/2;Il2rg
2/2
female were challenged with 453-EGFP cell either intramammary
or i.v. A dose of 50 mg/kg NVP-BKM120 was given by gavage
daily starting one or seven days after cell injection, control mice
Figure 3. Multiorgan inhibition of 453-EGFP metastatic growth by NVP-BKM120. Incidence of metastases in different sites (A) and local
tumor growth (B) after intramammary cell injection. Treatment with NVP-BKM120 started seven days after cell injection. Vehicle, n=6; NVP-BKM120,
n=5. (C) Incidence of metastases in different sites after intravenous cell injection. Vehicle, n=9; NVP-BKM120, n=6. Treatment with NVP-BKM120
started one day after cell injection. A significant inhibition of metastasis by NVP-BKM120 was recorded in the brain, bone marrow and liver, p,0.05 at
least, Fisher’s exact test. (D) Representative samples from groups of panel C of dissected control and treated mouse brains (ventral view) and lungs
showing reduction in metastatic burden by NVP-BKM120. Bars correspond to 2.5 mm (brain) or 7.5 mm (lungs).
doi:10.1371/journal.pone.0039626.g003
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the first week and five drug administrations in the following weeks,
for a total of 12 weeks (intramammary tumor cell challenge) or
7 weeks (i.v. challenge).
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded samples (2.5 mm
thick) were heated to 42uC and dehydrated in xylene and graded
alcohols. Antigen retrieval was performed in 10 mM citric acid
Figure 4. Quantitative analysis of antimetastatic activity of oral NVP-BKM120. Each bar represents the mean and SEM of groups of 6–9
mice treated i.v. with 453-EGFP cells, percentage inhibition is shown in each graph above NVP-BKM120 bar. (A) Metastatic burden in the brain as
evaluated by Real-Time PCR, see Materials and Methods for calculations; (B, C) Cytofluorometric determination of HER-2
+ metastatic cells in the
dissociated brain (B) and femural bone marrow (C); (D, E, F) Visual count of metastatic sites per mouse, see Fig. 1 for representative pictures. Statistical
evaluation of metastasis inhibition by NVP-BKM120: panels A, B, D, F, p,0.05 at least by the Student’s t test.
doi:10.1371/journal.pone.0039626.g004
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Medical, Concord, CA). Slides were allowed to cool for 5 minutes
in ice, followed by repeated rinsing with distilled water. Slides were
incubated with a 1:800 dilution of a rabbit polyclonal anti-Human
c-erbB-2 Oncoprotein (Dako Corporation, Carpinteria, CA –
USA), followed by a biotinylated goat anti – rabbit IgG (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA) secondary
antibody at 1:500 dilution. Immunoreactive antigens were
detected using Streptavidin Peroxidase (Thermo Scientific – Lab
Vision Corporation, Fremont, CA – USA) and DAB Chromogen
System (Dako).
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